For the millions of cancer patients who relapse after treatment, the culprit is increasingly traced not to the bulk tumor but to a resilient subpopulation of cells that behave like stem cells — capable of self-renewal, differentiation, and evasion of conventional therapies. Understanding what keeps these cells alive is now considered one of oncology's most urgent puzzles, with direct implications for reducing recurrence rates and improving long-term survival.
This review published in Acta Pharmacologica Sinica systematically maps the molecular machinery that sustains cancer stem cell (CSC) identity. Key signaling networks examined include Wnt/β-catenin, Notch, and Hedgehog pathways, which collectively regulate self-renewal and pluripotency in CSC populations across multiple tumor types. The analysis also addresses epigenetic regulators — including DNA methylation patterns and histone modification enzymes — as well as the tumor microenvironment's role in maintaining stemness through hypoxia-driven and metabolic cues. Critically, the review connects these mechanistic findings to therapeutic strategies currently in development or early clinical investigation, including pathway-specific inhibitors and combination approaches designed to eliminate CSC reservoirs rather than merely shrink tumor bulk.
The relevance of this synthesis extends well beyond academic oncology. CSCs are now widely implicated in chemotherapy resistance, metastatic seeding, and post-remission relapse — making them a central target in precision oncology. While the review is comprehensive in scope, the clinical translation of CSC-targeted therapies remains an ongoing challenge: many pathway inhibitors effective in preclinical models have shown limited single-agent efficacy in trials, often due to pathway redundancy and the adaptive plasticity of cancer cells. The conceptual value here is confirmatory and consolidating rather than paradigm-shifting, but it provides a well-organized framework for researchers and clinicians to evaluate where therapeutic leverage is most realistic. For health-conscious adults tracking cancer science, the takeaway is that eliminating treatment-resistant cancer reservoirs — not just tumor mass — is the frontier that may ultimately move survival statistics.